ACTRN12620001323910尚未招募未知
Application of the Multiphase Optimization Strategy to develop a multi-component initiative package to promote children’s vegetable intake in childcare - Evaluation Phase
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 284
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 2 Years 至 o limit（—）
- 性别
- All
入选标准
- •Private (non-Government) long day care centres, operating for at least eight hours per weekday (Monday to Friday), preparing food onsite, serving lunch and two between-meal snacks each day and enrolling children aged two to five years. All cooks and educators working at participating long day care centre and who give consent will be eligible to participate.
排除标准
- •Centres catering exclusively to children with special needs. Additionally, Centres that participated in the optimisation phase will be excluded. No exclusion criteria will be applied for children.
研究者
相似试验
已完成
不适用
Application of the Multiphase Optimization Strategy to develop a multi-component initiative package to promote children’s vegetable intake in childcareInsufficient vegetable intakeDiet and Nutrition - Other diet and nutrition disordersPublic Health - Health promotion/educationACTRN12620001301954Flinders University681
Unknown
Unknown
Assessment of a comprehensive strategy to optimize virological success in adolescents living with HIV and on antiretroviral treatment in the pediatric IeDEA West Africa collaboration: a stepped-wedge randomized cluster trial (OPTIMIZE-WA project)HIV/AIDSPACTR202402863175053ANRS MIE600
招募中
不适用
The DICTION studyPostoperative painNL-OMON21888Department of Anesthesiology, Amsterdam UMC, location AMC250
已完成
不适用
Investigation of the Optimal Treatment Strategy for Atrial Fibrillation in Japan -The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) StudyAtrial FibrillationJPRN-C000000106The J-RHYTHM Investigators2,600
招募中
不适用
Innovation of the 1st line strategy optimized as abemaciclib with endocrine therapy based on the ESR1 mutation of ctDNA for HR-positive HER2-negative advanced metastatic breast cancer patients - Multi-institutional phase 2 trial (JBCRG-M08)Hormone receptor-positive, HER2-negative inoperable or recurrent breast cancerJPRN-UMIN000051096Japan Breast Cancer Research Group (JBCRG)150